重组组织型纤维蛋白溶酶原激活剂,recombinant tissue plasminogen activater(rt-PA)
1)recombinant tissue plasminogen activater(rt-PA)重组组织型纤维蛋白溶酶原激活剂
2)recombinant human tissue plasminogen activator (tPA)重组人组织纤维蛋白溶酶原激活剂
3)tissue plasminogen activator组织型纤维蛋白溶解酶原激活剂
英文短句/例句
1.The thrombolytic effect of reteplase in treating rabbit retinal vein occlusion组织型纤维蛋白溶解酶原激活剂缺失突变体治疗兔视网膜静脉阻塞的疗效
2.Construction of Tissue Plasminogen Activator-annexin A5 Fusion Gene组织型纤溶酶原激活剂—膜联蛋白A5融合基因的构建
3.Expressions of Survivin and uPA in human cerebral gliomas脑胶质瘤组织中Survivin和尿激酶型纤溶酶原激活物蛋白的表达
4.Experimental Study on Posterior Vitreous Detachment Induced by Tissue Plasminogen Activator Combined with Hyaluronidase in Rabbits;组织纤维蛋白溶酶原激活剂联合透明质酸酶致玻璃体后脱离的动物实验研究
parison of Recombinant Tissue Plasminogen Activator, Urokinase and Defibrase in Vitro Simulation of Thrombolytic Test重组织型纤溶酶原激活剂、尿激酶和降纤酶体外溶栓效果比较
6.Role of Tissue-Type Plasminogen Activator in Neonatal Rat with Hypoxia-Ischemia Brain Damage组织纤维蛋白溶酶原激活剂在新生大鼠缺氧缺血性脑损伤中的作用
7.Clinical Study of the Expression of Tissue Factor and Urokinase Plasminogen Activator Receptor in Breast Cancer组织因子、尿激酶型纤溶酶原激活剂受体在乳腺癌中的表达
8.Evaluation of the therapeutic effect of thrombolytic therapy with rt-PA and nursing intervention in patients with acute myocardial infarction急性心肌梗死重组组织型纤溶酶原激活剂溶栓治疗的观察及护理
9.Therapeutic effect observation of thrombolysis with rt-PA intravenous in recurrent cerebral infarction重组组织型纤溶酶原激活剂对再发性脑梗死静脉溶栓治疗评价
10.Therapeutic Effect of Ultra Earlier Thrombolysis of Recombinant Tissue Plasminogen Activator in Acute Cerebral Infarction重组组织型纤溶酶原激活剂超早期溶栓治疗急性脑梗死的疗效
11.Thrombolytic therapy with intravenous recombinant tissue plasminogen activator for acute cerebral infarction重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死19例
12.Study on Recombinant Nonglycosylated Urokinase-type Plasminogen Activator;重组非糖基化尿激酶型纤溶酶原激活剂的研究
13.The Effect of Astragalus and Safflower Mixture on Expression of Plasminogen Activator Inhibitor 1 in Renal Tubulointerstitial Fibrosis in Rats with Unilateral Ureteral Obstruction;芪红合剂对肾间质纤维化模型大鼠肾组织中纤溶酶原激活物抑制物-1表达的影响
14.The Recombinant Human Tissue-type Plasminogen Activator in the Treatment of Deep Venous Thrombosis of the Lower Extremities重组组织型纤溶酶原激活剂治疗下肢深静脉血栓形成的临床应用
15.Experimental study on prevention of the peritoneal adhesion by recombinant tissue-type plasminogen activator on rats重组组织型纤溶酶原激活剂预防大鼠腹腔粘连的实验研究
16.Therapeutic effect evaluation of recombinant tissue plasminogen activator in hyper acute cerebral infarction重组组织型纤溶酶原激活剂治疗急性脑梗死的疗效评价
17.Construction of Tissue-type Plasminogen Activator Variants and Their Expression in Prokaryotic and Eukaryotic Cells;组织型纤溶酶原激活剂（t-PA）突变体的构建及其表达研究
18.Construction of Eukaryotic Expessing Vector of Tissue Plasminogen Activator (t-PA);组织型纤溶酶原激活剂（t-PA）真核表达载体的构建
相关短句/例句
recombinant human tissue plasminogen activator (tPA)重组人组织纤维蛋白溶酶原激活剂
3)tissue plasminogen activator组织型纤维蛋白溶解酶原激活剂
4)t-PA组织型纤维蛋白溶酶原激活剂
5)reteplase组织型纤维蛋白溶解酶原激活剂缺失突变体
1.The thrombolytic effect ofreteplase in treating rabbit retinal vein occlusion组织型纤维蛋白溶解酶原激活剂缺失突变体治疗兔视网膜静脉阻塞的疗效
6)tissue-typeplasminogenactivator组织型纤溶蛋白酶原激活剂
1.Objective To acquirethegenefragmentscodingfor humantissue-typeplasminogenactivator(ht-PA).目的获得编码人组织型纤溶蛋白酶原激活剂(humantissueplasminogenactivator,ht-PA)的基因。
延伸阅读
组织型纤维蛋白溶酶原激活剂分子式：CAS号：性质：又称组织型纤维蛋白溶酶原激活剂。天然物为单链分子，含527个氨基酸组成的糖蛋白。受纤溶酶或胰蛋白酶催化水解Arg275～Ile276肽后转变为由单二硫键相连的双链，其氨基端为重链(A链)，羧基端为轻链(B链)。轻链与胰蛋白酶等丝氨酸蛋白酶有很高的同源性，含有t-PA的活性中心His322，Asp371，Ser478。t-PA存在于人体很多组织和体液中溶解血纤维蛋白的丝氨酸蛋白(水解)酶。可选择性地高效激活血栓中纤溶酶原成为纤溶酶，后者水解血栓中的纤维蛋白。目前主要从人黑素瘤细胞培养物中提取t-PA，产品有单链和双链，分子量前者为67 000～68 000，后者两链分别为30 000和40 000。t-PA基因工程和蛋白质工程的目标是生产高效的药用t-PA产品。药用t-PA能高效地预防和治疗急性心肌梗塞等血栓性疾病。
